Moderna’s share price ended last week almost 8% higher after it received EU approval for its COVID-19 vaccine.
One of the three is a slam dunk to do so.
Investors may be tempted to invest in the hopes of a potential vaccine and big gains, but don’t be seduced by the hype and steer clear of this industry.
The key variable in this race is not the phase 3 trial, but which company has enough positive data for an Emergency Use Authorization.
Moderna’s latest vaccine news is not the first such story to influence the market, and it won’t be the last, but investors should be wary of this pattern
A gold stock and a COVID-19 play are both down more than 10% in the past month.
These two companies have emerged ahead of their competitors in having a medical intervention for the coronavirus epidemic.